NEWS
Special Reports
All News
FDA Briefs
Oncology Icons
The Targeted Pulse
CONFERENCES
Conference Coverage
Conference Listing
Data Dialogue with the Oncology Brothers
MEDIA
All Videos
Case-Based Peer Perspectives
Evolving Paradigms in Oncology
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Medical World News
Pivotal Practice Views with the Oncology Brothers
Podcasts
Practice Playbook
Shorts
Video Series
Webinars
PUBLICATIONS
All Publications
Evolving Paradigms
Peers & Perspectives in Oncology
Targeted Therapies in Oncology
More
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
CME/CE
Clinical Trials
Events
Precision Medicine Perspectives
Press Releases
Sponsored Content
Treatment Resources
SUBSCRIBE
Scout
Scout
NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE
BRAIN CANCER
BREAST CANCER
HER2 Breast Cancer
COMMUNITY ONCOLOGY PRACTICE
GENITOURINARY CANCERS
Bladder Cancer
Prostate Cancer
Renal Cell Carcinoma
GENOMIC TESTING
Liquid Biopsies
GI CANCERS
Pancreatic Cancer
Colorectal Cancer
Gastric Cancer
GIST
HCC
GYNECOLOGIC CANCERS
Cervical Cancer
Endometrial Cancer
Ovarian Cancer
HEAD & NECK CANCERS
HEMATOLOGY
Bone Marrow & Stem Cell Transplant
IMMUNOTHERAPY
CAR T-Cell Therapy
LEUKEMIAS
AML
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
LUNG CANCER
MET-Targeted Therapy
Small Cell Lung Cancer
Biomarker-Driven Lung Cancer
EGFR+ Lung Cancer
LYMPHOMAS
DLBCL
Follicular Lymphoma
Mantle Cell Lymphoma
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
ONCOLOGY POLICY
SARCOMA
SKIN CANCERS
Melanoma
THYROID CANCERS
Choose Specialty
Spotlight -
Community Oncology Practice
|
Oncology Policy
|
Myeloma
|
CLL
|
Genomic Testing
|
GU Cancers
Advertisement
Targeting CD19 in Diffuse Large B-Cell Lymphoma
EP. 1: Current Treatment Approach to Relapsed/Refractory DLBCL
By
Targeted Oncology
May 7th 2020
EP. 2: CD19-Targeted CAR T-Cell Therapy in Managing DLBCL
By
Targeted Oncology
May 7th 2020
EP. 3: CD19-Targeted MAbs in Relapsed/Refractory DLBCL
By
Targeted Oncology
May 7th 2020
EP. 4: Transplant Ineligibility: Anti-CD19 Combination Therapy
By
Targeted Oncology
May 7th 2020
EP. 5: L-MIND Combination Therapy Dosing Schedule
By
Targeted Oncology
May 7th 2020
EP. 6: Re-MIND Versus L-MIND Regimen
By
Targeted Oncology
May 7th 2020
EP. 7: CD19 and CD20 Antibodies in Development
By
Targeted Oncology
May 7th 2020
EP. 8: The Future of DLBCL Management
By
Targeted Oncology
May 7th 2020
EP. 9: Newly Diagnosed Relapsed/Refractory DLBCL
By
Targeted Oncology
May 7th 2020
EP. 10: CAR T: CD19-Targeted Therapy in R/R DLBCL
By
Targeted Oncology
May 7th 2020
EP. 11: Treatment of R/R DLBCL: CD19-Targeted Monoclonal Antibodies
By
Targeted Oncology
May 7th 2020
EP. 12: L-MIND Study: R/R DLBCL
By
Targeted Oncology
May 7th 2020
EP. 13: Future Directions for R/R DLBCL
By
Targeted Oncology
May 7th 2020
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CLL Treatment Enters a New Era of Targeted Combinations
2
Expanding the Role of Immunotherapy in Lymphoma
3
SurVaxM Improves OS Only in Younger Subgroup in Newly Diagnosed Glioblastoma
4
Psilocybin-Assisted Therapy Aims at Existential Distress in Lung Cancer
5
AI in Precision Oncology: A Paradigm Shift
